0001437749-23-023974.txt : 20230816 0001437749-23-023974.hdr.sgml : 20230816 20230816171927 ACCESSION NUMBER: 0001437749-23-023974 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20230815 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Submission of Matters to a Vote of Security Holders ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230816 DATE AS OF CHANGE: 20230816 FILER: COMPANY DATA: COMPANY CONFORMED NAME: WINDTREE THERAPEUTICS INC /DE/ CENTRAL INDEX KEY: 0000946486 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 943171943 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39290 FILM NUMBER: 231179104 BUSINESS ADDRESS: STREET 1: 2600 KELLY ROAD STREET 2: SUITE 100 CITY: WARRINGTON STATE: PA ZIP: 18976 BUSINESS PHONE: 2154889300 MAIL ADDRESS: STREET 1: 2600 KELLY ROAD STREET 2: SUITE 100 CITY: WARRINGTON STATE: PA ZIP: 18976 FORMER COMPANY: FORMER CONFORMED NAME: DISCOVERY LABORATORIES INC /DE/ DATE OF NAME CHANGE: 19971201 FORMER COMPANY: FORMER CONFORMED NAME: ANSAN PHARMACEUTICALS INC DATE OF NAME CHANGE: 19961121 FORMER COMPANY: FORMER CONFORMED NAME: ANSAN INC DATE OF NAME CHANGE: 19950609 8-K 1 wint20230816_8k.htm FORM 8-K wint20230816_8k.htm
false 0000946486 0000946486 2023-08-15 2023-08-15
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): August 15, 2023
 
Windtree Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
     
Delaware
001-39290
94-3171943
(State or other jurisdiction of
incorporation or organization)
(Commission
File Number)
(I.R.S. Employer
Identification No.)
 
2600 Kelly Road, Suite 100, Warrington, Pennsylvania
18976
(Address of principal executive offices)
(Zip Code)
 
Registrants telephone number, including area code: (215) 488-9300
 
Not Applicable
(Former name or former address, if changed since last report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
 
Trading
Symbol(s)
 
Name of each exchange
on which registered
Common Stock, par value $0.001 per share
 
WINT
 
The Nasdaq Capital Market
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ 
 
 

 
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
 
On August 15, 2023, at the Annual Meeting of Stockholders (the “Annual Meeting”) of Windtree Therapeutics, Inc. (the “Company”), stockholders of the Company approved an amendment and restatement of the Windtree Therapeutics 2020 Equity Incentive Plan (the “2020 Plan”) to (i) increase the authorized shares under the existing 2020 Equity Incentive Plan, by 645,000 shares, (ii) remove the 2020 Plan’s evergreen provision, (iii) clarify that no liberal share recycling will be permitted, (iv) impose a minimum vesting on awards granted under the 2020 Plan as described therein, and (v) prohibit dividend payments on unvested awards.
 
A detailed summary of the material features of the 2020 Plan is set forth in the Company’s definitive proxy statement for the Annual Meeting filed with the U.S. Securities and Exchange Commission on June 30, 2023 (the “Proxy Statement”) under the caption “Items To Be Voted On - Item 4: Approval of the Amended and Restated Windtree Therapeutics 2020 Equity Incentive Plan” which description is incorporated herein by reference.
 
The descriptions of the 2020 Plan contained herein and in the Proxy Statement do not purport to be complete and are qualified in their entirety by reference to the full text of the 2020 Plan, which is attached hereto as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.
 
Item 5.07
Submission of Matters to a Vote of Security Holders
 
On August 15, 2023, the Company held its Annual Meeting virtually. As of June 26, 2023, the record date for the Annual Meeting, there were 5,148,219 outstanding shares of the Company’s common stock. The following is a brief description of the final voting results for each of the proposals submitted to a vote of the stockholders at the Annual Meeting, which are described in detail in the Proxy Statement.
 
(a)          Proposal 1 — Election of the Five Director Nominees to Serve until the Companys 2024 Annual Meeting.
 
The votes with respect to the election of five directors to hold office until the 2024 annual meeting were as follows:
 
Director
Votes For
Votes Withheld
Broker Non-Votes
Craig E. Fraser
740,143
22,612
1,480,055
Daniel Geffken
728,246
34,509
1,480,055
Robert Scott, M.D.
591,638
171,117
1,480,055
Mark Strobeck, Ph.D.
729,893
32,862
1,480,055
Leslie J. Williams
567,849
194,906
1,480,055
 
(b)          Proposal 2 — Approval, on an Advisory Basis, of the Compensation of the Companys Named Executive Officers.
 
The votes with respect to the approval, on an advisory basis, of the compensation of the Company’s named executive officers were as follows:
 
Votes For
 
Votes Against
 
Abstentions
 
Broker Non-Votes
666,480
 
86,688
 
9,587
 
1,480,055
 
(c)          Proposal 3 — Ratification of Appointment of EisnerAmper LLP as the Companys Independent Registered Public Accounting Firm for 2023.
 
The votes with respect to the ratification of appointment of EisnerAmper LLP as the Company’s Independent Registered Public Accounting Firm for 2023 were as follows:
 
Votes For
 
Votes Against
 
Abstentions
 
Broker Non-Votes
2,120,083
 
48,301
 
74,426
 
N/A
 
 

 
(d)          Proposal 4 — Approval of the Amended and Restated Windtree Therapeutics 2020 Equity Incentive Plan.
 
The votes with respect to the approval of the Amended and Restated Windtree Therapeutics 2020 Equity Incentive Plan were as follows:
 
Votes For
 
Votes Against
 
Abstentions
 
Broker Non-Votes
669,259
 
88,539
 
4,957
 
1,480,055
 
 
Item 9.01         Financial Statements and Exhibits.
 
(d) Exhibits
 
The following exhibits are being filed herewith:
 
Exhibit
No.
 
Document
     
10.1
 
     
104
 
Cover Page Interactive Data File (embedded within the Inline XBRL document).
 
 

 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
 
Dated: August 16, 2023
Windtree Therapeutics, Inc.
By:
/s/ Craig E. Fraser
Name: Craig E. Fraser
Title: President and Chief Executive Officer
 
 
EX-10.1 2 ex_561548.htm EXHIBIT 10.1 ex_561548.htm

Exhibit 10.1

 

AMENDED AND RESTATED

 

WINDTREE THERAPEUTICS, INC.

 

2020 EQUITY INCENTIVE PLAN

 

Section 1. Purpose; Definitions. The purposes of the Amended and Restated Windtree Therapeutics, Inc. 2020 Equity Incentive Plan (as amended from time to time, the “Plan”) are to: (a) enable Windtree Therapeutics, Inc. (the “Company”) and its affiliated companies to recruit and retain highly qualified employees, directors and consultants; (b) provide those employees, directors and consultants with an incentive for productivity; and (c) provide those employees, directors and consultants with an opportunity to share in the growth and value of the Company.

 

For purposes of the Plan, the following terms will have the meanings defined below, unless the context clearly requires a different meaning:

 

(a) “Affiliate” means, with respect to a Person, a Person that directly or indirectly controls, is controlled by, or is under common control with such Person.

 

(b) “Applicable Law” means the legal requirements relating to the administration of and issuance of securities under stock incentive plans, including, without limitation, the requirements of state corporations law, federal, state and foreign securities law, federal, state and foreign tax law, and the requirements of any stock exchange or quotation system upon which the Shares may then be listed or quoted.

 

(c) “Award” means an award of Options, Stock Appreciation Rights, Restricted Stock, Restricted Stock Units or Cash or Other Stock Based Awards made under this Plan.

 

(d) “Award Agreement” means, with respect to any particular Award, the written document that sets forth the terms of that particular Award.

 

(e) “Board” means the Board of Directors of the Company, as constituted from time to time.

 

(f) “Cash or Other Stock Based Award” means an award that is granted under Section 10.

 

(g) “Cause” shall, with respect to any Participant, have the meaning set forth in the Participant’s employment, consulting or other applicable agreement, or, in the absence of any such agreement or if such term is not defined in any such agreement, shall mean any one or more of the following, as determined by the Committee: (i) willful misconduct or gross negligence in the performance of the Participant’s duties; (ii) willful and continued failure or refusal to perform satisfactorily any duties reasonably requested in the course of the Participant’s employment by, or service to, the Company (other than a failure resulting from the Participant’s Disability); or (iii) fraudulent, dishonest or other improper conduct engaged in by the Participant that causes, or has the potential to cause, harm to the Company or any of its Subsidiaries, or its or their business or reputation, including, without limitation, the Participant’s violation of any policies of the Company applicable to the Participant, the Participant’s violation of laws, rules or regulations applicable to the Participant, criminal activity, habitual drunkenness or use of illegal drugs. 

 

(h) “Change in Control” shall have the meaning, if any, set forth in a Participant’s employment, consulting or other applicable agreement, or, if such term is not defined in any such agreement, shall mean either a “Change in Control” as defined in Section 1(h)(i) or a “409A Change in Control” as defined in Section 1(h)(ii), as specified in the applicable Award Agreement. If no definition is specified, the term shall mean a 409A Change in Control.

 

 

 

(i) A “Change in Control” shall mean the occurrence of any of the following events:

 

(A) the acquisition, directly or indirectly by any Person (other than the Company, any trustee or other fiduciary under an employee benefit plan of the Company, or a person that directly or indirectly controls, is controlled by, or is under common control with, the Company), of beneficial ownership (within the meaning of Rule 13d-3 of the Exchange Act) of securities possessing more than thirty-five percent (35%) of the total combined voting power of the Company’s outstanding securities;

 

(B) a change in the composition of the Board over a period of thirty-six (36) consecutive months or less such that a majority of the Board ceases to consist of “incumbent members”, which term means members of the Board on the first day of such period and any person becoming a member of the Board subsequent to such date whose election or nomination for election was approved by not less than two-thirds of the members of the Board who then comprised the “incumbent members”;

 

(C) the Company combines with another company and is the surviving corporation but, immediately after the combination, the shareholders of the Company immediately prior to the combination hold, directly or indirectly, by reason of their being stockholders of the Company, fifty percent (50%) or less of the voting stock of the combined entity; or

 

(D) a liquidation of the Company, a sale of all or substantially all of the Company’s assets, or a merger, consolidation or similar transaction in which the Company is not the surviving entity or survives as a wholly-owned or majority-owned subsidiary of another entity.

 

(ii) A “409A Change in Control” shall mean the occurrence of any of the following events:

 

(A) any Person (other than (1) the Company, or (2) any trustee or other fiduciary under an employee benefit plan of the Company), is or becomes the beneficial owner (as defined in Rule 13d-3 under the 1934 Act), directly or indirectly, of securities of the Company by reason of having acquired such securities during the 12-month period ending on the date of the most recent acquisition (not including any securities acquired directly from the Company or its Affiliates) representing thirty percent (30%) or more of the total voting power of the Company’s then outstanding voting securities;

 

(B) the majority of members of the Board is replaced during any 12-month period by directors whose appointment or election is not endorsed by a majority of the members of the Board before the date of the appointment;

 

(C) there is consummated a merger or consolidation of Company with any other corporation or other entity, resulting in a change described in clauses (A), (B), (D), or (E) of this definition, other than (1) a merger or consolidation that would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving or parent entity) more than sixty percent (60%) of the total voting power of the voting securities of the Company or such surviving or parent entity outstanding immediately after such merger or consolidation or (2) a merger or consolidation effected to implement a recapitalization of the Company (or similar transaction) in which no Person, directly or indirectly, acquired forty percent (40%) or more of the total voting power of the then outstanding securities of the Company (not including any securities acquired directly from the Company or its Affiliates);

 

(D) a liquidation of the Company involving the sale to any Person of at least forty percent (40%) of the total gross fair market value of all of the assets of the Company immediately before the liquidation; or

 

(E) the sale or disposition by the Company of assets that have a total fair market value equal to forty percent (40%) or more of the total gross fair market value of all of the assets of the Company and its Subsidiaries (taken as a whole) immediately before such sale or disposition (or any transaction or related series of transactions having a similar effect), other than a sale or disposition by the Company to an entity at least sixty percent (60%) of the total voting power of the voting securities of which is beneficially owned by shareholders of the Company in substantially the same proportions as their beneficial ownership of the Company immediately prior to such sale.

 

 

 

(i) “Code” means the Internal Revenue Code of 1986, as amended from time to time, and any successor thereto.

 

(j) “Committee” means the committee designated by the Board to administer the Plan under Section 2. To the extent required under Applicable Law, the Committee shall have at least two members and each member of the Committee shall be a Non-Employee Director.

 

(k) “Director” means a member of the Board.

 

(l) “Disability” means a condition rendering a Participant Disabled.

 

(m) “Disabled” will have the same meaning as set forth in Section 22(e)(3) of the Code.

 

(n) “Effective Date” will have the same meaning as set forth in Section 18.

 

(o) “Exchange Act” means the Securities Exchange Act of 1934, as amended.

 

(p) “Fair Market Value” means, as of any date, the value of a Share determined as follows: (i) if the Shares are listed on any established stock exchange or a national market system, the Fair Market Value of a Share will be the closing sales price for such stock as quoted on that system or exchange (or the system or exchange with the greatest volume of trading in Shares) at the close of regular hours trading on the day of determination; (ii) if the Shares are regularly quoted by recognized securities dealers but selling prices are not reported, the Fair Market Value of a Share will be the mean between the high bid and low asked prices for Shares at the close of regular hours trading on the day of determination; or (iii) if Shares are not traded as set forth above, the Fair Market Value will be determined in good faith by the Committee taking into consideration such factors as the Committee considers appropriate, such determination by the Committee to be final, conclusive and binding. Notwithstanding the foregoing, in connection with a Change in Control, Fair Market Value shall be determined in good faith by the Committee, such determination by the Committee to be final conclusive and binding.

 

(q) “Incentive Stock Option” means any Option intended to be an “Incentive Stock Option” within the meaning of Section 422 of the Code.

 

(r) “Minimum Vesting Period” means the one-year period following the date of grant of an Award.

 

(s)“Non-Employee Director” will have the meaning set forth in Rule 16b-3(b)(3)(i) promulgated by the Securities and Exchange Commission under the Exchange Act, or any successor definition adopted by the Securities and Exchange Commission.

 

(t) “Non-Qualified Stock Option” means any Option that is not an Incentive Stock Option.

 

(u) “Option” means any option to purchase Shares (including an option to purchase Restricted Stock, if the Committee so determines) granted pursuant to Section 5 hereof.

 

(v) “Parent” means, in respect of the Company, a “parent corporation” as defined in Section 424(e) of the Code.

 

(w) “Participant” means an employee, consultant, Director, or other service provider of or to the Company or any of its respective Affiliates to whom an Award is granted.

 

(x) “Person” means an individual, partnership, corporation, limited liability company, trust, joint venture, unincorporated association, or other entity or association.

 

(y) “Restricted Stock” means Shares that are subject to restrictions pursuant to Section 8 hereof.

 

(z) “Restricted Stock Unit” means a right granted under and subject to restrictions pursuant to Section 9 hereof.

 

 

 

(aa) “Shares” means shares of the Company’s common stock, par value $0.001, subject to substitution or adjustment as provided in Section 3(c) hereof.

 

(bb) “Stock Appreciation Right” means a right granted under and subject to Section 6 hereof.

 

(cc) “Subsidiary” means, in respect of the Company, a subsidiary company as defined in Sections 424(f) and (g) of the Code.

 

Section 2. Administration. The Plan shall be administered by the Committee; provided that, notwithstanding anything to the contrary herein, in its sole discretion, the Board may at any time and from time to time exercise any and all rights and duties of the Committee under the Plan except with respect to matters which under Applicable Law are required to be determined in the sole discretion of the Committee. Any action of the Committee in administering the Plan shall be final, conclusive and binding on all persons, including the Company, its Subsidiaries, Affiliates, their respective employees, the Participants, persons claiming rights from or through Participants and stockholders of the Company.

 

The Committee will have full authority to grant Awards under this Plan and determine the terms of such Awards. Such authority will include the right to:

 

(a) select the individuals to whom Awards are granted (consistent with the eligibility conditions set forth in Section 4);

 

(b) determine the type of Award to be granted;

 

(c) determine the number of Shares, if any, to be covered by each Award;

 

(d) establish the other terms and conditions of each Award;

 

(e) approve forms of agreements (including Award Agreements) for use under the Plan; and

 

(f) modify or amend each Award, subject to the Participant’s consent if such modification or amendment would materially impair such Participant’s rights.

 

The Committee will have the authority to adopt, alter and repeal such administrative rules, guidelines and practices governing the Plan as it, from time to time, deems advisable; to interpret the terms and provisions of the Plan and any Award issued under the Plan (and any Award Agreement); and to otherwise take any action that may be necessary or desirable to facilitate the administration of the Plan. The Committee may correct any defect, supply any omission or reconcile any inconsistency in the Plan or in any Award Agreement in the manner and to the extent it deems necessary to carry out the intent of the Plan.

 

To the extent permitted by Applicable Law, the Committee may delegate to one or more officers of the Company the authority to grant Awards to Participants who are not subject to the requirements of Section 16 of the Exchange Act and the rules and regulations thereunder. Any such delegation shall be subject to the applicable corporate laws of the State of Delaware. The Committee may revoke any such allocation or delegation at any time for any reason with or without prior notice.

 

No Director will be liable for any good faith determination, act or omission in connection with the Plan or any Award.

 

Section 3. Shares Subject to the Plan.

 

(a) Shares Subject to the Plan. Subject to adjustment as provided in Section 3(c) of the Plan, the maximum number of Shares that may be issued in respect of Awards under the Plan is 738,175 Shares (the “Plan Limit”). All of the Plan Limit Shares may be issued in respect of Incentive Stock Options. Any Shares issued hereunder may consist, in whole or in part, of authorized and unissued Shares or treasury shares. Any Shares issued by the Company through the assumption or substitution of outstanding grants in connection with the acquisition of another entity shall not reduce the maximum number of Shares available for delivery under the Plan. Any Shares that are available for issuance under the Windtree Therapeutics, Inc. 2011 Long-Term Incentive Plan (as amended) (the “2011 Plan”) as of the Effective Date, and any Shares that become available for issuance under the 2011 Plan following the Effective Date in accordance with the terms of the 2011 Plan (the “Additional Shares”), may be issued to Participants pursuant to the terms of this Plan. The Plan Limit shall be increased by such number of Additional Shares.

 

 

 

(b) Effect of the Expiration or Termination of Awards. If and to the extent that an Option or a Stock Appreciation Right expires, terminates or is canceled or forfeited for any reason without having been exercised in full, the Shares associated with that Award will again become available for grant under the Plan. Similarly, if and to the extent an Award of Restricted Stock or Restricted Stock Units is canceled or forfeited for any reason, the Shares subject to that Award will again become available for grant under the Plan. For purposes of this limitation described in Section 3(a) above, the shares of Stock underlying any awards under the Plan that are forfeited, canceled, held back upon exercise of an Option or settlement of an Award to cover the exercise price or tax withholding, reacquired by the Company prior to vesting, satisfied without the issuance of Shares or otherwise terminated (other than by exercise) shall not be added back to the Shares available for issuance under the Plan or the Shares that may be issued as Incentive Stock Options. In the event the Company repurchases Shares on the open market, such Shares shall not be added to the Shares available for issuance under the Plan.

 

(c) Other Adjustment. In the event of any corporate event or transaction such as a merger, consolidation, reorganization, recapitalization, stock split, reverse stock split, split up, spin-off, combination of shares, exchange of shares, stock dividend, dividend in kind, or other like change in capital structure (other than ordinary cash dividends) to stockholders of the Company, or other similar corporate event or transaction affecting the Shares, the Committee, to prevent dilution or enlargement of Participants’ rights under the Plan, shall, in such manner as it may deem equitable, substitute or adjust, in its sole discretion, the number and kind of shares that may be issued under the Plan or under any outstanding Awards, the number and kind of shares subject to outstanding Awards, the exercise price, grant price or purchase price applicable to outstanding Awards, and/or any other affected terms and conditions of this Plan or outstanding Awards.

 

(d) Change in Control. Notwithstanding anything to the contrary set forth in the Plan, upon or in anticipation of any Change in Control, the Committee may, in its sole and absolute discretion and without the need for the consent of any Participant, take one or more of the following actions contingent upon the occurrence of that Change in Control:

 

(i) cause any or all outstanding Awards to become vested and immediately exercisable (as applicable), in whole or in part;

 

(ii) cause any outstanding Option or Stock Appreciation Right to become fully vested and immediately exercisable for a reasonable period in advance of the Change in Control and, to the extent not exercised prior to that Change in Control, cancel that Option or Stock Appreciation Right upon closing of the Change in Control;

 

(iii) cancel any unvested Award or unvested portion thereof, with or without consideration;

 

(iv) cancel any Award in exchange for a substitute award;

 

(v) redeem any Restricted Stock or Restricted Stock Unit for cash and/or other substitute consideration with value equal to the Fair Market Value of an unrestricted Share on the date of the Change in Control;

 

(vi) cancel any Option or Stock Appreciation Right in exchange for cash and/or other substitute consideration with a value equal to: (A) the number of Shares subject to that Option or Stock Appreciation Right, multiplied by (B) the difference, if any, between the Fair Market Value per Share on the date of the Change in Control and the exercise price of that Option or the base price of the Stock Appreciation Right; provided, that if the Fair Market Value per Share on the date of the Change in Control does not exceed the exercise price of any such Option or the base price of any such Stock Appreciation Right, the Committee may cancel that Option or Stock Appreciation Right without any payment of consideration therefor; and/or

 

 

 

(vii) take such other action as the Committee shall determine to be reasonable under the circumstances.

 

In the discretion of the Committee, any cash or substitute consideration payable upon cancellation of an Award may be subjected to (i) vesting terms substantially identical to those that applied to the cancelled Award immediately prior to the Change in Control, or (ii) earn-out, escrow, holdback or similar arrangements, to the extent such arrangements are applicable to any consideration paid to stockholders in connection with the Change in Control.

 

Notwithstanding any provision of this Section 3(d), in the case of any Award subject to Section 409A of the Code, the Committee shall only be permitted to take actions under this Section 3(d) to the extent that such actions would be consistent with the intended treatment of such Award under Section 409A of the Code.

 

(e) Foreign Holders. Notwithstanding any provision of the Plan to the contrary, in order to comply with the laws in countries other than the United States in which the Company and its Subsidiaries operate or have employees, directors and consultants, or in order to comply with the requirements of any foreign securities exchange or other Applicable Law, the Committee, in its sole discretion, shall have the power and authority to: (i) modify the terms and conditions of any Award granted to employees, directors and consultants outside the United States to comply with Applicable Law (including, without limitation, applicable foreign laws or listing requirements of any foreign securities exchange); (ii) establish subplans and modify exercise procedures and other terms and procedures, to the extent such actions may be necessary or advisable; provided, however, that no such subplans and/or modifications shall increase the share limitations contained in Section 3(a); and (iii) take any action, before or after an Award is made, that it deems advisable to obtain approval or comply with any necessary local governmental regulatory exemptions or approvals or listing requirements of any foreign securities exchange.

 

(f) Minimum Vesting Period. The vesting period for each Award granted under the Plan must be at least equal to the Minimum Vesting Period; provided, however, nothing in this Section 3(f) shall limit the Administrator’s authority to accelerate the vesting of Awards as set forth in Section 3(d)(i) above; and, provided further, notwithstanding the foregoing, up to 5% of the shares of Stock authorized for issuance under the Plan may be utilized for Awards to receive unrestricted shares or other Awards with a vesting period that is less than the Minimum Vesting Period (each such Award, an “Excepted Award”). Notwithstanding the foregoing, in addition to Excepted Awards, the Administrator may grant Awards that vest (or permit previously granted Awards to vest) within the Minimum Vesting Period (i) if such Awards are granted as substitute Awards in replacement of other Awards (or awards previously granted by an entity being acquired (or assets of which are being acquired)) that were scheduled to vest within the Minimum Vesting Period or (ii) if such Awards are being granted in connection with an elective deferral of cash compensation that, absent a deferral election, otherwise would have been paid to the grantee within the Minimum Vesting Period.

 

Section 4. Eligibility. Employees, Directors, consultants, and other individuals who provide services to the Company or its Affiliates are eligible to be granted Awards under the Plan; provided, however, that only employees of the Company, any Parent or a Subsidiary are eligible to be granted Incentive Stock Options.

 

Section 5. Options. Options granted under the Plan may be of two types: (i) Incentive Stock Options or (ii) Non-Qualified Stock Options. The Award Agreement shall state whether such grant is an Incentive Stock Option or a Non-Qualified Stock Option.

 

The Award Agreement evidencing any Option will incorporate the following terms and conditions and will contain such additional terms and conditions, not inconsistent with the terms of the Plan, as the Committee deems appropriate in its sole and absolute discretion:

 

(a) Option Price. The exercise price per Share under an Option will be determined by the Committee and will not be less than 100% of the Fair Market Value of a Share on the date of the grant. However, any Incentive Stock Option granted to any Participant who, at the time the Option is granted, owns, either directly and/or within the meaning of the attribution rules contained in Section 424(d) of the Code, stock possessing more than 10% of the total combined voting power of all classes of stock of the Company, will have an exercise price per Share of not less than 110% of Fair Market Value per Share on the date of the grant.

 

 

 

(b) Option Term. The term of each Option will be fixed by the Committee, but no Option will be exercisable more than 10 years after the date the Option is granted. However, any Incentive Stock Option granted to any Participant who, at the time such Option is granted, owns, either directly and/or within the meaning of the attribution rules contained in Section 424(d) of the Code, stock possessing more than 10% of the total combined voting power of all classes of stock of the Company, may not have a term of more than 5 years. No Option may be exercised by any Person after expiration of the term of the Option.

 

(c) Exercisability. Options will vest and be exercisable at such time or times and subject to such terms and conditions as determined by the Committee. Such terms and conditions may include the continued employment or service of the Participant, the attainment of specified individual or corporate performance goals, or such other factors as the Committee may determine in its sole discretion (the “Vesting Conditions”). The Committee may provide in the terms of an Award Agreement that the Participant may exercise the unvested portion of an Option in whole or in part in exchange for shares of Restricted Stock subject to the same vesting terms as the portion of the Option so exercised. Restricted Stock acquired upon the exercise of an unvested Option shall be subject to such additional terms and conditions as determined by the Committee.

 

(d) Method of Exercise. Subject to the terms of the applicable Award Agreement, the exercisability provisions of Section 5(c) and the termination provisions of Section 7, Options may be exercised in whole or in part from time to time during their term by the delivery of written notice to the Company specifying the number of Shares to be purchased. Such notice will be accompanied by payment in full of the purchase price, either by certified or bank check, or such other means as the Committee may accept. The Committee may, in its sole discretion, permit payment of the exercise price of an Option in the form of previously acquired Shares based on the Fair Market Value of the Shares on the date the Option is exercised or by means of a “net settlement,” whereby the Option exercise price will not be due in cash and where the number of Shares issued upon such exercise will be equal to: (A) the product of (i) the number of Shares as to which the Option is then being exercised, and (ii) the excess, if any, of (a) the then current Fair Market Value per Share over (b) the Option exercise price, divided by (B) the then current Fair Market Value per Share.

 

No Shares will be issued upon exercise of an Option until full payment therefor has been made. A Participant will not have the right to distributions or dividends or any other rights of a stockholder with respect to Shares subject to the Option until the Participant has given written notice of exercise, has paid in full for such Shares, if requested, has given the representation described in Section 17(a) hereof and fulfills such other conditions as may be set forth in the applicable Award Agreement.

 

(e) Incentive Stock Option Limitations. In the case of an Incentive Stock Option, the aggregate Fair Market Value (determined as of the time of grant) of the Shares with respect to which Incentive Stock Options are exercisable for the first time by the Participant during any calendar year under the Plan and/or any other plan of the Company, its Parent or any Subsidiary will not exceed $100,000. For purposes of applying the foregoing limitation, Incentive Stock Options will be taken into account in the order granted. To the extent any Option does not meet such limitation, that Option will be treated for all purposes as a Non-Qualified Stock Option.

 

(f) Termination of Service. Unless otherwise specified in the applicable Award Agreement or as otherwise provided by the Committee at or after the time of grant, Options will be subject to the terms of Section 7 with respect to exercise upon or following termination of employment or other service.

 

Section 6. Stock Appreciation Right. Subject to the other terms of the Plan, the Committee may grant Stock Appreciation Rights to eligible individuals. Each Stock Appreciation Right shall represent the right to receive, upon exercise, an amount equal to the number of Shares subject to the Award that is being exercised multiplied by the excess of (i) the Fair Market Value of a Share on the date the Award is exercised, over (ii) the base price specified in the applicable Award Agreement. Distributions may be made in cash, Shares, or a combination of both, at the discretion of the Committee. The Award Agreement evidencing each Stock Appreciation Right shall indicate the base price, the term and the Vesting Conditions for such Award. A Stock Appreciation Right base price may never be less than the Fair Market Value of the underlying common stock of the Company on the date of grant of such Stock Appreciation Right. The term of each Stock Appreciation Right will be fixed by the Committee, but no Stock Appreciation Right will be exercisable more than 10 years after the date the Stock Appreciation Right is granted. Subject to the terms and conditions of the applicable Award Agreement, Stock Appreciation Rights may be exercised in whole or in part from time to time during their term by the delivery of written notice to the Company specifying the portion of the Award to be exercised. Unless otherwise specified in the applicable Award Agreement or as otherwise provided by the Committee at or after the time of grant, Stock Appreciation Rights will be subject to the terms of Section 7 with respect to exercise upon or following termination of employment or other service.

 

 

 

Section 7. Termination of Service. Unless otherwise specified with respect to a particular Option or Stock Appreciation Right in the applicable Award Agreement or otherwise determined by the Committee, any portion of an Option or Stock Appreciation Right that is not exercisable upon termination of service will expire immediately and automatically upon such termination and any portion of an Option or Stock Appreciation Right that is exercisable upon termination of service will expire on the date it ceases to be exercisable in accordance with this Section 7.

 

(a) Termination by Reason of Death. If a Participant’s service with the Company or any Affiliate terminates by reason of death, any Option or Stock Appreciation Right held by such Participant may thereafter be exercised, to the extent it was exercisable at the time of his or her death or on such accelerated basis as the Committee may determine at or after grant, by the legal representative of the estate or by the legatee of the Participant, for a period expiring (i) at such time as may be specified by the Committee at or after grant, or (ii) if not specified by the Committee, then 12 months from the date of death, or (iii) if sooner than the applicable period specified under (i) or (ii) above, upon the expiration of the stated term of such Option or Stock Appreciation Right.

 

(b) Termination by Reason of Disability. If a Participant’s service with the Company or any Affiliate terminates by reason of Disability, any Option or Stock Appreciation Right held by such Participant may thereafter be exercised by the Participant or his or her personal representative, to the extent it was exercisable at the time of termination, or on such accelerated basis as the Committee may determine at or after grant, for a period expiring (i) at such time as may be specified by the Committee at or after grant, or (ii) if not specified by the Committee, then 90 days from the date of termination of service, or (iii) if sooner than the applicable period specified under (i) or (ii) above, upon the expiration of the stated term of such Option or Stock Appreciation Right.

 

(c) Cause. If a Participant’s service with the Company or any Affiliate is terminated for Cause or if a Participant resigns at a time that there was a Cause basis for such Participant’s termination: (i) any Option or Stock Appreciation Right, or portion thereof, not already exercised will be immediately and automatically forfeited as of the date of such termination, and (ii) any Shares for which the Company has not yet delivered share certificates will be immediately and automatically forfeited and the Company will refund to the Participant the Option exercise price paid for such Shares, if any.

 

(d) Other Termination. If a Participant’s service with the Company or any Affiliate terminates for any reason other than death, Disability or Cause, any Option or Stock Appreciation Right held by such Participant may thereafter be exercised by the Participant, to the extent it was exercisable at the time of such termination, or on such accelerated basis as the Committee may determine at or after grant, for a period expiring (i) at such time as may be specified by the Committee at or after grant, or (ii) if not specified by the Committee, then three months from the date of termination of service, or (iii) if sooner than the applicable period specified under (i) or (ii) above, upon the expiration of the stated term of such Option or Stock Appreciation Right.

 

Section 8. Restricted Stock.

 

(a) Issuance. Restricted Stock may be issued either alone or in conjunction with other Awards. The Committee will determine the time or times within which Restricted Stock may be subject to forfeiture, and all other conditions of such Awards. The purchase price for Restricted Stock may, but need not, be zero.

 

 

 

(b) Certificates. Upon the Award of Restricted Stock, the Committee may direct that a certificate or certificates representing the number of Shares subject to such Award be issued to the Participant or placed in a restricted stock account (including an electronic account) with the transfer agent and in either case designating the Participant as the registered owner. The certificate(s), if any, representing such shares shall be physically or electronically legended, as applicable, as to sale, transfer, assignment, pledge or other encumbrances during the Restriction Period. If physical certificates are issued, they will be held in escrow by the Company or its designee during the Restriction Period. As a condition to any Award of Restricted Stock, the Participant may be required to deliver to the Company a share power, endorsed in blank, relating to the Shares covered by such Award.

 

(c) Restrictions and Conditions. The Award Agreement evidencing the grant of any Restricted Stock will incorporate the following terms and conditions and such additional terms and conditions, not inconsistent with the terms of the Plan, as the Committee deems appropriate in its sole and absolute discretion:

 

(i) During a period commencing with the date of an Award of Restricted Stock and ending at such time or times as specified by the Committee (the “Restriction Period”), the Participant will not be permitted to sell, transfer, pledge, assign or otherwise encumber Restricted Stock awarded under the Plan. The Committee may condition the lapse of restrictions on Restricted Stock upon one or more Vesting Conditions.

 

(ii) While any Share of Restricted Stock remains subject to restriction, the Participant will have, with respect to the Restricted Stock, the right to vote the Shares. If any cash distributions or dividends are payable with respect to the Restricted Stock for which the lapse of restrictions is tied to the attainment of vesting conditions, any dividends paid by the Company during the vesting period shall accrue and shall not be paid to the grantee until and to the extent the vesting conditions are met with respect to the Restricted Stock Award. A Participant shall not be entitled to interest with respect to any dividends or distributions subject to vesting conditions during the Restriction Period.

 

(iii) Subject to the provisions of the applicable Award Agreement or as otherwise determined by the Committee, if a Participant’s service with the Company and its Affiliates terminates prior to the expiration of the applicable Restriction Period, the Participant’s Restricted Stock that then remains subject to forfeiture will then be forfeited automatically.

 

Section 9. Restricted Stock Units. Subject to the other terms of the Plan, the Committee may grant Restricted Stock Units to eligible individuals and may impose one or more Vesting Conditions on such units. Each Restricted Stock Unit will represent a right to receive from the Company, upon fulfillment of any applicable conditions, an amount equal to the Fair Market Value (at the time of the distribution) of one Share. Distributions may be made in cash, Shares, or a combination of both, at the discretion of the Committee. The Award Agreement evidencing a Restricted Stock Unit shall set forth the Vesting Conditions and time and form of payment with respect to such Award. The Participant shall not have any stockholder rights with respect to the Shares subject to a Restricted Stock Unit Award until that Award vests and the Shares are actually issued thereunder; provided, however, that an Award Agreement may provide for the inclusion of dividend equivalent payments or unit credits with respect to the Award in the discretion of the Committee; provided, however, that any such dividend equivalents shall accrue and shall not be paid to the grantee until and to the extent the vesting conditions are met with respect to the Restricted Stock Unit Award to which they relate. A Participant shall not be entitled to interest with respect to any dividend equivalents or other distributions subject to vesting conditions during the Restriction Period. Subject to the provisions of the applicable Award Agreement or as otherwise determined by the Committee, if a Participant’s service with the Company terminates prior to the Restricted Stock Unit Award vesting in full, any portion of the Participant’s Restricted Stock Units that then remain subject to forfeiture will then be forfeited automatically.

 

Section 10. Cash or Other Stock Based Awards. Subject to the other terms of the Plan, the Committee may grant Cash or Other Stock Based Awards (including Awards to receive unrestricted Shares or immediate cash payments) to eligible individuals. The Award Agreement evidencing a Cash or Other Stock Based Award shall set forth the terms and conditions of such Cash or Other Stock Based Award, including, as applicable, the term, any exercise or purchase price, performance goals, Vesting Conditions and other terms and conditions. Payment in respect of a Cash or Other Stock Based Award may be made in cash, Shares, or a combination of cash and Shares, as determined by the Committee.

 

 

 

Section 11. Amendments and Termination. Subject to any shareholder approval that may be required under Applicable Law, the Plan may be amended or terminated at any time or from time to time by the Board.

 

Section 12. Prohibition on Repricing Programs. Neither the Committee nor the Board shall (i) implement any cancellation/re-grant program pursuant to which outstanding Options or Stock Appreciation Rights under the Plan are cancelled and new Options or Stock Appreciation Rights are granted in replacement with a lower exercise or base price per share, (ii) cancel outstanding Options or Stock Appreciation Rights under the Plan with exercise prices or base prices per share in excess of the then current Fair Market Value per Share for consideration payable in equity securities of the Company or (iii) otherwise directly reduce the exercise price or base price in effect for outstanding Options or Stock Appreciation Rights under the Plan, without in each such instance obtaining stockholder approval.

 

Section 13. Conditions Upon Grant of Awards and Issuance of Shares.

 

(a) The implementation of the Plan, the grant of any Award and the issuance of Shares in connection with the issuance, exercise or vesting of any Award made under the Plan shall be subject to the Company’s procurement of all approvals and permits required by regulatory authorities having jurisdiction over the Plan, the Awards made under the Plan and the Shares issuable pursuant to those Awards.

 

(b) No Shares or other assets shall be issued or delivered under the Plan unless and until there shall have been compliance with all applicable requirements of Applicable Law.

 

Section 14. Limits on Transferability; Beneficiaries. No Award or other right or interest of a Participant under the Plan shall be pledged, encumbered, or hypothecated to, or in favor of, or subject to any lien, obligation, or liability of such Participant to, any party, other than the Company, any Subsidiary or Affiliate, or assigned or transferred by such Participant other than by will or the laws of descent and distribution, and such Awards and rights shall be exercisable during the lifetime of the Participant only by the Participant or his or her guardian or legal representative. Notwithstanding the foregoing, the Committee may, in its discretion, provide that Awards or other rights or interests of a Participant granted pursuant to the Plan (other than an Incentive Stock Option) be transferable, without consideration, to immediate family members (i.e., children, grandchildren or spouse), to trusts for the benefit of such immediate family members and to partnerships in which such family members are the only partners. The Committee may attach to such transferability feature such terms and conditions as it deems advisable. In addition, a Participant may, in the manner established by the Committee, designate a beneficiary (which may be a person or a trust) to exercise the rights of the Participant, and to receive any distribution, with respect to any Award upon the death of the Participant. A beneficiary, guardian, legal representative or other person claiming any rights under the Plan from or through any Participant shall be subject to all terms and conditions of the Plan and any Award Agreement applicable to such Participant, except as otherwise determined by the Committee, and to any additional restrictions deemed necessary or appropriate by the Committee.

 

Section 15. Withholding of Taxes.

 

(a) Required Withholding. All Awards under the Plan shall be subject to applicable federal (including FICA), state and local tax withholding requirements. The Company may require that the Participant or other person receiving or exercising Awards pay to the Company the amount of any federal, state or local taxes that the Company is required to withhold with respect to such Awards, or the Company may deduct from other wages paid by the Company the amount of any withholding taxes due with respect to such Awards.

 

(b) Election to Withhold Shares. If the Committee so permits, Shares subject to an Award may be withheld to satisfy tax withholding obligations arising with respect thereto based on the Fair Market Value of such Shares at the time of withholding, to the extent that such withholding would not result in liability classification of such Award (or any portion thereof) under applicable accounting rules.

 

 

 

Section 16. Liability of Company.

 

(a) Inability to Obtain Authority. If the Company cannot, by the exercise of commercially reasonable efforts, obtain authority from any regulatory body having jurisdiction for the sale of any Shares under this Plan, and such authority is deemed by the Company’s counsel to be necessary to the lawful issuance of those Shares, the Company will be relieved of any liability for failing to issue or sell those Shares.

 

(b) Grants Exceeding Allotted Shares. If Shares subject to an Award exceed, as of the date of grant, the number of Shares which may be issued under the Plan without additional stockholder approval, that Award will be contingent with respect to such excess Shares, on the effectiveness under Applicable Law of a sufficient increase in the number of Shares subject to this Plan.

 

(c) Rights of Participants and Beneficiaries. The Company will pay all amounts payable under this Plan only to the applicable Participant, or beneficiaries entitled thereto pursuant to this Plan. The Company will not be liable for the debts, contracts, or engagements of any Participant or his or her beneficiaries, and rights to cash payments under this Plan may not be taken in execution by attachment or garnishment, or by any other legal or equitable proceeding while in the hands of the Company.

 

Section 17. General Provisions.

 

(a) The Board may require each Participant to represent to and agree with the Company in writing that the Participant is acquiring securities of the Company for investment purposes and without a view to distribution thereof and as to such other matters as the Board believes are appropriate.

 

(b) The Awards shall be subject to the Company’s stock ownership policies, as in effect from time to time.

 

(c) All certificates for Shares or other securities delivered under the Plan will be subject to such share-transfer orders and other restrictions as the Board may deem advisable under the rules, regulations and other requirements of the Securities Act of 1933, as amended, the Exchange Act, any stock exchange upon which the Shares are then listed, and any other Applicable Law, and the Board may cause a legend or legends to be put on any such certificates to make appropriate reference to such restrictions.

 

(d) Nothing contained in the Plan will prevent the Board from adopting other or additional compensation arrangements, subject to stockholder approval if such approval is required.

 

(e) Neither the adoption of the Plan nor the execution of any document in connection with the Plan will: (i) confer upon any employee or other service provider of the Company or an Affiliate any right to continued employment or engagement with the Company or such Affiliate, or (ii) interfere in any way with the right of the Company or such Affiliate to terminate the employment or engagement of any of its employees or other service providers at any time.

 

(f) The Awards (whether vested or unvested) shall be subject to rescission, cancellation or recoupment, in whole or in part, under any current or future “clawback” or similar policy of the Company that is applicable to the Participant. Notwithstanding any other provisions in this Plan, any Award which is subject to recovery under any law, government regulation or stock exchange listing requirement, will be subject to such deductions and clawback as may be required to be made pursuant to such law, government regulation or stock exchange listing requirement.

 

Section 18. Effective Date of Plan. The Plan shall be effective as of January 20, 2021 (the “Effective Date”).

 

Section 19. Term of Plan. Unless the Plan is terminated in accordance with Section 11, the Plan shall terminate December 24, 2030, ten years after the date the majority stockholders approved the Plan. No Awards under the Plan shall thereafter be granted.

 

 

 

Section 20. Invalid Provisions. In the event that any provision of this Plan is found to be invalid or otherwise unenforceable under any Applicable Law, such invalidity or unenforceability will not be construed as rendering any other provisions contained herein as invalid or unenforceable, and all such other provisions will be given full force and effect to the same extent as though the invalid or unenforceable provision was not contained herein.

 

Section 21. Governing Law. The Plan and all Awards granted hereunder will be governed by and construed in accordance with the laws and judicial decisions of the State of Delaware, without regard to the application of the principles of conflicts of laws.

 

Section 22. Notices. Any notice to be given to the Company pursuant to the provisions of this Plan must be given in writing and addressed, if to the Company, to its principal executive office to the attention of its Chief Financial Officer (or such other Person as the Company may designate in writing from time to time), and, if to a Participant, to the address contained in the Company’s personnel files, or at such other address as that Participant may hereafter designate in writing to the Company. Any such notice will be deemed duly given: if delivered personally or via recognized overnight delivery service, on the date and at the time so delivered; if sent via telecopier or email, on the date and at the time telecopied or emailed with confirmation of delivery; or, if mailed, five (5) days after the date of mailing by registered or certified mail.

 

 
EX-101.SCH 3 wint-20230815.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink EX-101.DEF 4 wint-20230815_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 5 wint-20230815_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity [Domain] Legal Entity [Axis] Document Information [Line Items] Document Information [Table] Document, Type Document, Period End Date Entity, Registrant Name Entity, Incorporation, State or Country Code Entity, File Number Entity, Tax Identification Number Entity, Address, Address Line One Entity, Address, City or Town Entity, Address, State or Province Entity, Address, Postal Zip Code City Area Code Local Phone Number Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security Trading Symbol Security Exchange Name Entity, Emerging Growth Company Amendment Flag Entity, Central Index Key EX-101.PRE 6 wint-20230815_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.2
Document And Entity Information
Aug. 15, 2023
Document Information [Line Items]  
Entity, Registrant Name Windtree Therapeutics, Inc.
Document, Type 8-K
Document, Period End Date Aug. 15, 2023
Entity, Incorporation, State or Country Code DE
Entity, File Number 001-39290
Entity, Tax Identification Number 94-3171943
Entity, Address, Address Line One 2600 Kelly Road, Suite 100
Entity, Address, City or Town Warrington
Entity, Address, State or Province PA
Entity, Address, Postal Zip Code 18976
City Area Code 215
Local Phone Number 488-9300
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock
Trading Symbol WINT
Security Exchange Name NASDAQ
Entity, Emerging Growth Company false
Amendment Flag false
Entity, Central Index Key 0000946486
XML 8 wint20230816_8k_htm.xml IDEA: XBRL DOCUMENT 0000946486 2023-08-15 2023-08-15 false 0000946486 8-K 2023-08-15 Windtree Therapeutics, Inc. DE 001-39290 94-3171943 2600 Kelly Road, Suite 100 Warrington PA 18976 215 488-9300 false false false false Common Stock WINT NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( &V*$%<'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " !MBA!70Q!#"N\ K @ $0 &1O8U!R;W!S+V-O&ULS9)1 M2\,P$,>_BN2]O2;%H:'KBV-/"H(#Q;>0W+9@DX;DI-VW-ZU;A^@'\#%W__SN M=W"-#E+W$9]C'S"2Q70SNLXGJ<.:'8F"!$CZB$ZE,B=\;N[[Z!3E9SQ 4/I# M'1!$5:W (2FC2,$$+,)"9&UCM-01%?7QC#=ZP8?/V,TPHP$[=.@I 2\YL':: M&$YCU\ 5,,$(HTO?!30+<:[^B9T[P,[),=DE-0Q#.=1S+N_ X>WI\65>M[ ^ MD?(:\Z]D)9T"KMEE\FO]L-EM62LJ41?57<%7.\$EOY?B]GUR_>%W%7:]L7O[ MCXTO@FT#O^ZB_0)02P,$% @ ;8H05YE&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M M3A^%$5B-;'EDD81_OTV23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R M> +]O6N[!3+ MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,! M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2 MBW A(5M>5 TR M6'!VULS2 Y9>*?IUE!K9';O=05SP6.XYB1'^QL4$UFG2&98T1G*=D 4. #?$ MT4Q0?*]!MHK@PI+27)#6SRFU4!H(FLB!]4>"(<7K;YH] M5Z%82=J$^!!&&N*<<^9ST6S[!Z5&T?95O-RCEU@5 9<8WS2J-2S%UGB5P/&M MG#P=$Q+-E L&08:7)"82J3E^34@3_BNEVOZKR2.FJW"$2M"/F(9 M-AIRM1:!MG&IA&!:$L;1>$[2M!'\6:PUDSY@R.S-D77.UI$.$9)>-T(^8LZ+ MD!&_'H8X2IKMHG%8!/V>7L-)P>B"RV;]N'Z&U3-L+([W1]072N0/)J<_Z3(T M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+ M.7\N?<^E[[GT/:'2MSAD6R4)RU3393>* M$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.WF)&Y M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_# M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0 MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYNTB42%(JP# 4A M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF M8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.' MYA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?-2K6J5D*Q$_ M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]! MU4#E/]O4#6CV#30,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04 M" !MBA!7>3-$0DP$ "G$ & 'AL+W=OB\%&Z5>SYMR2]S219NBMK)$X)./[=BWKE,]W MX_9!_;%X>7B9!3/\3B4O(K;KH=?S2,R7+$_LL]K\SO$!??N007E/;-L--!J0[3K#6JN M4;QJ,1K@A'2S,K,:[@H89T?W*LHAR):,94P>I!5V2R9R-]L0M8%OX2&NJQ_M M!6]W@N$)P7&^NB*T$&>^4H8JQF@ M/[&4UV'B0B]"QE9S3N9KKEG&4^9U2[;N61,) 5_[J+P555@N+N7DSC&#ZD3J/@ B'M8"!5':"XD7]2$<1DNE82 MLY &D7:O=]EOX2E?U02*._F+%M9R"8%)TUSN__94\\L(PL-A@15?1W,N8Z[)E^7RQ/SA M>HUD50&@N%U_1S8Q)@>R1D!L6^="NO#W%OGFL6NQ2;;=.%JDVP!H&7R=,<(ZEL/<0=^! 5 M\O >K9E<\9/?L U"3^/9_?@KQG2T$3C/SA]2KEZL=[OBW8E56;$372@+^]JB MN>8,;,%U@/M+I>SAQ&UNR]\F1O\!4$L#!!0 ( &V*$%>?H!OPL0( .(, M - >&PO9KEMWDOSAR+DCO9*Z MW="C<\W[)&D/1ZY8^\XT7'ND,E8QYU5;)VUC.2M;<%(R6=[<9(EB0M-BK3MU MIUQ+#J;3;D-O:%*L*Z//EI0&@U_*%">/3&[HEDFQMV)8RY20IV!>@N%@I+'$ M>2I\0Q=@:9\"O @:L!SC**&-!6,2,H3O_;C\&3!IK5>%E#/!)0V&8MTPY[C5 M=UX9%@_&%Q 9Y=VI\0QKRTZ+Y2T].PP_/LG>V)+;.'36-/+T M08I:*Q[V_LL)BS6;_,C16/'DL\&D'+R!6TH>N77B<&GY85FSX[V;IJFO<,[+ M?Y#SGZUSS36W3%Z2]J/_-U?Y+8R3\?1<'-&K SI;"5R$&_H5[E=YYD#VG9!. MZ%$[BK+D^L4Y]>$=V_L+_"J^7U_RBG72[69P0\_R%UZ*3N7SJGNHR[CJ+'^& M^VB1S;>PSR5TR7M>;D?5UOM!)%[P6<<'')XC=\,31S"?@,41P+ \& /,)WAA M>?ZG_:S0_00,X[:*(BO49X7Z!*\8LAT^6)ZX3^Z?^$[S/$VS#*OH=AMEL,7J MEF7P%X^&<0,/+ ]D>ENM\6[C$_+Z'& ]?6U"L)WBDXCM%*\U(/&Z@4>>Q[N- MY0$/K O8[$#^>!Z8J;A/FD)7,6[8"<:1/,<0F,7XC&894IT,/O'^8* \^>Q\ETWLJ.?]74_P$4$L#!!0 ( &V* M$%>7BKL

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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 1 22 1 false 0 0 false 0 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.wint.com/20230815/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false All Reports Book All Reports wint20230816_8k.htm ex_561548.htm wint-20230815.xsd wint-20230815_def.xml wint-20230815_lab.xml wint-20230815_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "wint20230816_8k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "contextCount": 1, "dts": { "definitionLink": { "local": [ "wint-20230815_def.xml" ] }, "inline": { "local": [ "wint20230816_8k.htm" ] }, "labelLink": { "local": [ "wint-20230815_lab.xml" ] }, "presentationLink": { "local": [ "wint-20230815_pre.xml" ] }, "schema": { "local": [ "wint-20230815.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/currency/2023/currency-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/exch/2023/exch-2023.xsd", "https://xbrl.sec.gov/sic/2023/sic-2023.xsd", "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" ] } }, "elementCount": 26, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2023": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "wint", "nsuri": "http://www.wint.com/20230815", "report": { "R1": { "firstAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "wint20230816_8k.htm", "contextRef": "d20238K", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000 - Document - Document And Entity Information", "menuCat": "Cover", "order": "1", "role": "http://www.wint.com/20230815/role/statement-document-and-entity-information", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "body", "html" ], "baseRef": "wint20230816_8k.htm", "contextRef": "d20238K", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.wint.com/20230815/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.wint.com/20230815/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.wint.com/20230815/role/statement-document-and-entity-information" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document, Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.wint.com/20230815/role/statement-document-and-entity-information" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document, Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.wint.com/20230815/role/statement-document-and-entity-information" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity, Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.wint.com/20230815/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity, Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.wint.com/20230815/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity, Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.wint.com/20230815/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity, Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.wint.com/20230815/role/statement-document-and-entity-information" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity, Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.wint.com/20230815/role/statement-document-and-entity-information" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.wint.com/20230815/role/statement-document-and-entity-information" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity, Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.wint.com/20230815/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity, File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.wint.com/20230815/role/statement-document-and-entity-information" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity, Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.wint.com/20230815/role/statement-document-and-entity-information" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity, Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.wint.com/20230815/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity, Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.wint.com/20230815/role/statement-document-and-entity-information" ], "xbrltype": "employerIdItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.wint.com/20230815/role/statement-document-and-entity-information" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.wint.com/20230815/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.wint.com/20230815/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.wint.com/20230815/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.wint.com/20230815/role/statement-document-and-entity-information" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.wint.com/20230815/role/statement-document-and-entity-information" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.wint.com/20230815/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.wint.com/20230815/role/statement-document-and-entity-information" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.wint.com/20230815/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 15 0001437749-23-023974-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001437749-23-023974-xbrl.zip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